A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma

Trial Profile

A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs RPL 554 (Primary) ; Salbutamol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Verona Pharma
  • Most Recent Events

    • 18 May 2016 Status changed from active, no longer recruiting to completed, as per results presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results (n = 25) presented at the 112th International Conference of the American Thoracic Society.
    • 27 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top